Rouan Sarah Kathryn's Form 4 filing
Viking Therapeutics, Inc. (VKTX) · filed Apr 2, 2025
- Accession no.
- 0000950170-25-049717
- Filed
- Apr 2, 2025
- Trade date
- Mar 31, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $29.9K. It was filed 2 days after the trade.
This filing was later replaced by the amendment 0000950170-25-052255 (Apr 8, 2025). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rouan Sarah KathrynCIK 0001761366 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 31, 2025 | Common Stock, par value $0.00001 per share | PPurchaseAcquired | +1,240 | $24.15 | +$29,946 | 1,240 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.